mibefradil withdrawn
Selected indexed studies
- Mibefradil withdrawn from the market. (Ann Pharmacother, 1998) [PMID:9681103]
- T-type Ca(2+) Channels: T for Targetable. (Cancer Res, 2018) [PMID:29343521]
- Nonlinear kinetics and pharmacologic response to mibefradil. (Clin Pharmacol Ther, 2000) [PMID:10741628]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Mibefradil withdrawn from the market. (1998) pubmed
- T-type Ca(2+) Channels: T for Targetable. (2018) pubmed
- Nonlinear kinetics and pharmacologic response to mibefradil. (2000) pubmed
- Drug-drug interactions of new active substances: mibefradil example. (1999) pubmed
- Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study. (2015) pubmed
- Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. (1999) pubmed
- The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. (2008) pubmed
- T-type calcium channel blockade in the management of chronic ischemic heart disease. (2000) pubmed
- Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6',7'-Dihydroxybergamottin. (2019) pubmed
- Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes. (2024) pubmed